Literature DB >> 10920728

Homocysteine: to screen and treat or to wait and see?

J Genest1, M C Audelin, E Lonn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10920728      PMCID： PMC1232548     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Vitamin E supplementation and cardiovascular events in high-risk patients.

Authors:  S Yusuf; G Dagenais; J Pogue; J Bosch; P Sleight
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.

Authors:  M R Malinow; A G Bostom; R M Krauss
Journal:  Circulation       Date:  1999 Jan 5-12       Impact factor: 29.690

3.  Lipid-lowering drugs and homocysteine.

Authors:  M de Lorgeril; P Salen; F Paillard; P Lacan; G Richard
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

Review 4.  Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.

Authors:  J W Eikelboom; E Lonn; J Genest; G Hankey; S Yusuf
Journal:  Ann Intern Med       Date:  1999-09-07       Impact factor: 25.391

Review 5.  Homocysteine and cardiovascular disease.

Authors:  H Refsum; P M Ueland; O Nygård; S E Vollset
Journal:  Annu Rev Med       Date:  1998       Impact factor: 13.739
  5 in total
  2 in total

Review 1.  Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia.

Authors:  Brahmajee K Nallamothu; A Mark Fendrick; Gilbert S Omenn
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications.

Authors:  G J Hankey; J W Eikelboom
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.